HC Wainwright Issues Pessimistic Forecast for Geron Earnings

Geron Corporation (NASDAQ:GERN) – Investment analysts at HC Wainwright dropped their FY2026 earnings estimates for Geron in a research note issued to investors on Wednesday, August 5th. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will post earnings of ($0.05) per share for the year, down from their prior forecast of ($0.02). The consensus estimate for Geron’s current full-year earnings is ($0.02) per share.

Separately, Weiss Ratings lowered shares of Geron from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 24th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $4.00.

Geron Stock Performance

NASDAQ GERN opened at $1.57 on Friday. The firm has a 50-day moving average of $1.34 and a 200-day moving average of $1.46. The company has a debt-to-equity ratio of 0.52, a quick ratio of 4.96 and a current ratio of 6.78. The stock has a market cap of $1.01 billion, a PE ratio of -14.27 and a beta of 0.61. Geron has a 52-week low of $1.04 and a 52-week high of $2.01.

Geron (NASDAQ:GERN) last released its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.01). The company had revenue of $57.48 million during the quarter, compared to analyst estimates of $55.30 million. Geron had a negative net margin of 34.17% and a negative return on equity of 24.06%.

Institutional Trading of Geron

Several institutional investors have recently added to or reduced their stakes in GERN. 55 North Private Wealth LLC bought a new position in Geron during the 4th quarter worth $29,000. LCM Capital Management Inc boosted its position in shares of Geron by 80.6% in the fourth quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 10,000 shares during the period. Vistica Wealth Advisors LLC acquired a new position in shares of Geron in the fourth quarter valued at about $33,000. Hsbc Holdings PLC acquired a new position in shares of Geron in the first quarter valued at about $33,000. Finally, Caitong International Asset Management Co. Ltd increased its position in Geron by 3,307.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 24,410 shares during the period. 73.71% of the stock is currently owned by institutional investors.

Key Headlines Impacting Geron

Here are the key news stories impacting Geron this week:

• Positive Sentiment: RYTELO (imetelstat) net product revenue reached a record $57.5 million, up 11% sequentially and above analyst expectations of $55.3 million. The company reiterated its 2026 RYTELO revenue outlook of $220 million to $240 million. Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
• Positive Sentiment: Geron ended the quarter with $327 million in cash, restricted cash and marketable securities, supporting continued commercialization of RYTELO and development activities. Management also appointed Chinmaya Rath as chief business officer. Company Results and Business Highlights
• Positive Sentiment: Call-option activity surged, with investors buying 10,326 calls—about 14 times the average volume—indicating heightened speculative interest and potentially bullish positioning.
• Neutral Sentiment: The earnings call focused on the RYTELO commercial launch, revenue growth and business execution. Geron Q2 2026 Earnings Call Transcript
• Negative Sentiment: Geron reported a quarterly loss of $0.02 per share, missing the consensus loss estimate of $0.01. The company continues to report negative profitability metrics, including a negative net margin and return on equity. Geron Second-Quarter Earnings Report
• Negative Sentiment: HC Wainwright lowered its EPS forecasts for 2027 through 2030: estimates fell to $0.02, $0.12, $0.32 and $0.55, respectively. The reductions imply slower expected earnings growth and likely weighed on the stock. Geron Analyst Estimates

About Geron

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.